Skip to main content

Table 1 Baseline characteristics (mean/SD) of the two groups of endometriotic patients having GnRH agonist or Dienogest as a pretreatment before ART

From: Role of suppression of endometriosis with progestins before IVF-ET: a non-inferiority randomized controlled trial

  GnRH agonist Dienogest P-value
Age (years)a 35.6 ± 3.5 36.1 ± 2.7 0.24
BMI (Kg/m2)a 22.5 ± 1.6 22.3 ± 1.9 0.18
Duration of subfertilitya 6.6 ± 1.5 7.2 ± 1.7 0.1
Previous ART (%) b 20/67 (29.85%) 17/67 (25.37%) 0.56
Previous live birth (%) b 10/67 (14.93%) 10/67 (14.93%) 1
Cause of infertility (%) b
 Male 25 (37.31%) 27 (40.3%)
 Anovulation 27 (40.3%) 30 (44.78%)
 Tubal 32 (47.76%) 32 (47.76%)
 uterine 23 (34.33%) 30 (44.78%)
Stage of Endometriosis b
 Minimal 5/67 (7.46%) 8/67 (11.94%) 0.69
 Mild 13/67 (19.4%) 12/67 (17.91%)
 Moderate 27/67 (40.3%) 22/67 (32.84%)
 Severe 22/67 (32.84%) 25/67 (37.31%)
FSH (IU/L)a 5.4 ± 1.7 4.3 ± 1.8 0.22
AMH (ng/ml)a 3.5 ± 1.3 2.8 ± 1.8 0.07
AFCa 12 ± 3.2 11.8 ± 2.3 0.08
  1. FSH Follicle-stimulating Hormone, AMH Anti-Mullerian Hormone, AFC Antral Follicle Count
  2. aValues are expressed as means ± standard deviations
  3. bValues expressed as percentages